Never miss a story

Get subscribed to our newsletter


×
Type-2 diabetes occurs when insulin becomes less efficient. Unsplash

Examining the role of cholesterol in both Alzheimer’s disease and Type-2 diabetes, researchers have identified a small molecule that may help regulate cholesterol levels in the brain, making it a potential new therapeutic target for Alzheimer’s disease. There is no known cure for Alzheimer’s disease and in the last decade, scientists have found increasing evidence linking the underlying causes of Type 2 diabetes and Alzheimer’s disease.

Type-2 diabetes occurs when insulin becomes less efficient at removing glucose from the bloodstream, resulting in high blood sugar that can cause abnormal cholesterol levels. A similar situation occurs in Alzheimer’s disease, but rather than affecting the body as a whole, the effects are localized in the brain.


Follow NewsGram on LinkedIn to know what’s happening around the world.

“Alzheimer’s and diabetes share many common causes,” said study co-author Gregory Thatcher, Professor at the University of Arizona College of Pharmacy.

“Our goal was to develop a way of identifying compounds that would counteract many detrimental changes that contribute to both Alzheimer’s and Type-2 diabetes,” Thatcher added.


APOE is one of the proteins involved in reverse cholesterol transport. Pixabay

When cholesterol rises, due to insulin resistance or other factors, the body starts a process is known as reverse cholesterol transport, during which specific molecules carry excess cholesterol to the liver to be excreted. Apolipoprotein E (APOE) is one of the proteins involved in reverse cholesterol transport. APOE is also the strongest risk factor gene for Alzheimer’s disease and related dementia, and an independent risk factor for Type 2 diabetes and cardiovascular disease.

ALSO READ: Report: Concerning Increase In Levels Of BP, Cholesterol, And Diabetes

Similarly, reduced activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), correlates with increased risk of cardiovascular disease, Type-2 diabetes, and Alzheimer’s disease. Increasing the activity of ABCA1 is expected to positively influence insulin signaling and reduce inflammation in the brain, making it a potential therapy for both Type-2 diabetes and Alzheimer’s disease.

In this study published in the journal ACS Pharmacology and Translational Science, Thatcher and the research team designed a way to identify small molecules that improve the function of ABCA1 in the body while avoiding unwanted effects to the liver. (IANS/SP)


Popular

Unsplash

Robots evolve to do more work around us

As robots evolve to do more work around us, the UK-based humanoid robot manufacturer Engineered Arts has infused more human-like facial expressions into one of its robots, which may leave you with an eerie feeling.

In a video posted on YouTube, the robot called 'Ameca' displays various human expressions, like appearing to "wake up" from sleep, as its face shows confusion and frustration when it opens its eyes.

Follow NewsGram on Twitter to stay updated about the World news.

Keep Reading Show less
Unsplash

The Microsoft office

Microsoft has disrupted the activities of a China-based hacking group, gaining control of the malicious websites the group used to attack organisations in the US and 28 other countries around the world.

The Microsoft Digital Crimes Unit (DCU) said in a statement that a federal court in Virginia granted its request to seize websites of the hacking group called 'Nickel', enabling the company to cut off Nickel's access to its victims and prevent the websites from being used to execute attacks.

Keep Reading Show less
Unsplash

MediaTek's plans to boost technology democratisation and enable access to disruptive connectivity

Chip manufacturer MediaTek on Monday announced that it is focused on making 2022 a year aimed at rapid growth, business success, substantial expansion in Research and Development capabilities.

MediaTek's plans to boost technology democratisation and enable access to disruptive connectivity with its range of mainstream to flagship 5G chips.

"We at MediaTek are focused on making 2022 a year aimed at rapid growth, business success, and substantial expansion in our R&D capabilities. For 2022, we are focused on further strengthening our presence in India, offering incredible experiences to customers, and supporting the country's technology initiatives with our expertise and collaboration with leading OEMs," Anku Jain, Managing Director, MediaTek India said in a statement.

Follow NewsGram on LinkedIn to know what's happening around the world.

In the flagship segment, MediaTek recently announced the Dimensity 9000 chip, which is a milestone of innovation and a rise to the incredible, built-to-power flagship 5G smartphones in the world, the company claims.

MediaTek Dimensity 9000 features a single Cortex-X2 performance core clocked at 3.05GHz, three Cortex-A710 cores at 2.85GHz and four Cortex-A510 efficiency cores at 1.8GHz.

It packs a 10-core Arm Mali-G710 that takes care of graphics processing, the report said.

Keep reading... Show less